Thomas G. DeLoughery, MD
Potential Financial Conflicts of Interest:Consultancies: GlaxoSmithKline. Honoraria: Baxter, GlaxoSmithKline, Sanofi-Aventis.
Requests for Single Reprints: Thomas G. DeLoughery, MD, Divisions of Hematology/Medical Oncology and Laboratory Medicine, Oregon Health & Science University, Hematology L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098; e-mail, firstname.lastname@example.org.
Adapted for publication in Annals of Internal Medicine by Jennifer Fisher Wilson and Michael Berkwits, MD, MSCE.
DeLoughery TG. Update in Hematology. Ann Intern Med. 2007;147:717-724. doi: 10.7326/0003-4819-147-10-200711200-00008
Download citation file:
Published: Ann Intern Med. 2007;147(10):717-724.
This Update in Hematology reviews the past year's most important articles relevant to hematology. The Table(1, 2) summarizes changes to clinical practice that should emerge from these articles.
Question: What dose of rivaroxaban, a direct factor Xa inhibitor, is safest and most effective for the prevention of venous thromboembolism (VTE) after total hip replacement?
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only